Video
Alan G. Wade, the founder of CPS Research, talks about how they analyze the microbiota to assess the impact of probiotics on health.
In precision cancer care, the microbiota cannot be put aside. We talked about this with James Kinross from the Imperial College London.
Antonio Gasbarrini from the Gemelli Hospital in Rome explains how the modulation of the intestinal microbiota is entering medicine.
Probiotics: 2019 will be crucial for scientific and regulatory aspects with help coming also from Venture Capital. Denise Kelly from Seventure talks about it.
The development of probiotics presents major regulatory challenges. We discussed it this Clara Desvignes from Voisin Consulting Life Sciences.
MetaboGen is active in the field of live biotherapeutic products and on the study of liver diseases. We discussed their approach with Sara Malcus, CEO of the company.
New technologies such as the analysis of the "aquatic microbiota" allow to dig deeply into the microbiome chemistry. We discuss this approach with Ross Youngs, CEO of Biosortia.
Prof. Lars Engstrand from the Karolinska Institutet, in Stockholm, Sweden, explains how studying the vaginal microbiota could impact on reproductive medicine.
According to J. Kinross, from Imperial College London, there's an urgent need to understand the role of the intestinal microbiome in the etiology of cancer.
According to Prof. Ted Dinan, who has been investigating the brain-intestinal axis for years, the gut microbiota plays a role in the genesis of depression.
